BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) immunotherapy bispecific antibody BNT327 for solid tumors. The candidate ...

Under the agreed deal, Bristol-Myers Squibb Company (NYSE:BMY) will pay $1.5 billion upfront to co-develop BioNTech’s experimental cancer drug, BNT327, and obtain its commercialization rights.

Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of ...

Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines Krebsmedikaments der nächsten Generation zahlen. Dies ist ein Zeichen des ...

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types ; MAINZ, Germany, ...

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co ...

MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into ...

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types.